Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
|Podcasts|February 17, 2021
Core2Scan - Process Tracking & Compliance Support with RFID
Author(s)Veltek Associates, Inc.
Core2Scan® is a complete RFID tracking solution designed for the pharmaceutical and biotech industry. Core2Scan® can track assets, people, raw material, and inventory. The asset tracking piece incorporates asset management tools for monitoring equipment calibration, PM, and service requests. This solution can also be used for process improvement, allowing you to track asset and personnel flow throughout your facility. Compliance support is built into Core2Scan®. The system provides a history of all asset movement, giving users a thorough and documented audit trail. Core2Scan® includes hardware, software, and RFID tags that can all be used in and out of the cleanroom. With software that supports 21 CFR Part 11 compliance, you will have a tool that meets your needs.
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
Trending on Pharmaceutical Technology
1
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
4
Our Biggest Takeaways From AAPS PharmSci 360
5